DK2366393T3 - Roflumilast til behandlingen af pulmonal hypertension - Google Patents
Roflumilast til behandlingen af pulmonal hypertensionInfo
- Publication number
- DK2366393T3 DK2366393T3 DK11168764.6T DK11168764T DK2366393T3 DK 2366393 T3 DK2366393 T3 DK 2366393T3 DK 11168764 T DK11168764 T DK 11168764T DK 2366393 T3 DK2366393 T3 DK 2366393T3
- Authority
- DK
- Denmark
- Prior art keywords
- roflumilast
- treatment
- pulmonary hypertension
- hypertension
- pulmonary
- Prior art date
Links
- 208000002815 pulmonary hypertension Diseases 0.000 title 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 title 1
- 229960002586 roflumilast Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05103147 | 2005-04-19 | ||
| EP06725734A EP1874309A1 (en) | 2005-04-19 | 2006-04-12 | Roflumilast for the treatment of pulmonary hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2366393T3 true DK2366393T3 (da) | 2013-10-21 |
Family
ID=34939388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11168764.6T DK2366393T3 (da) | 2005-04-19 | 2006-04-12 | Roflumilast til behandlingen af pulmonal hypertension |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8648100B2 (da) |
| EP (2) | EP2366393B1 (da) |
| JP (2) | JP2008536888A (da) |
| KR (1) | KR101358479B1 (da) |
| CN (2) | CN102614176A (da) |
| AU (1) | AU2006237300B2 (da) |
| BR (1) | BRPI0610498A2 (da) |
| CA (1) | CA2604295C (da) |
| CY (1) | CY1114468T1 (da) |
| DK (1) | DK2366393T3 (da) |
| EA (1) | EA016037B1 (da) |
| ES (1) | ES2433661T3 (da) |
| HR (1) | HRP20130982T1 (da) |
| IL (2) | IL186538A0 (da) |
| ME (1) | ME01609B (da) |
| MX (1) | MX2007012711A (da) |
| NO (1) | NO20075662L (da) |
| NZ (1) | NZ561746A (da) |
| PL (1) | PL2366393T3 (da) |
| PT (1) | PT2366393E (da) |
| RS (1) | RS52944B (da) |
| SI (1) | SI2366393T1 (da) |
| WO (1) | WO2006111495A1 (da) |
| ZA (1) | ZA200707930B (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009013286A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Organic compounds |
| WO2009115235A1 (en) * | 2008-03-20 | 2009-09-24 | Bayer Schering Pharma Aktiengesellschaft | Pde inhibitors for the treatment of pulmonary hypertension |
| SI2948148T1 (sl) | 2013-01-28 | 2020-12-31 | Incozen Therapeutics Pvt. Ltd. | Postopki za zdravljenje avtoimunskih, respiratornih in vnetnih obolenj z inhalacijo roflumilast N-oksida |
| US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
| CN107038965A (zh) * | 2017-05-05 | 2017-08-11 | 深圳浩翔光电技术有限公司 | Led显示装置、成型模组、及其生产工艺 |
| KR20190005708A (ko) | 2017-07-05 | 2019-01-16 | 이화여자대학교 산학협력단 | 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물 |
| CN115969847A (zh) * | 2023-02-03 | 2023-04-18 | 华中科技大学 | 罗氟司特在制备治疗心力衰竭的药物中的应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB371800A (en) | 1929-10-21 | 1932-04-28 | Willem Zaadnoordijk | A process of filtering gases and fogs |
| GB343664A (en) | 1929-12-27 | 1931-02-26 | William Duncan Grant | Subaquatic rock drilling devices |
| GB357903A (en) | 1931-01-05 | 1931-10-01 | Oskar Rosenfelder | Improvements in catamenial appliances and infants' diapers |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| DE59410119D1 (de) | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| US5728705A (en) | 1993-10-04 | 1998-03-17 | The Trustees Of Columbia University In The City Of New York | Method of inducing vasorelaxation to treat pulmonary hypertension |
| GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
| US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| PT975347E (pt) | 1997-02-28 | 2008-05-23 | Nycomed Gmbh | Combinação sinérgica de inibidores da pde e agonistas da adenilato ciclase ou agonistas da guanil ciclise |
| EA002057B1 (ru) | 1997-04-25 | 2001-12-24 | Пфайзер Инк. | ПИРАЗОЛОПИРИМИДИНОНЫ, КОТОРЫЕ ИНГИБИРУЮТ ЦИКЛИЧЕСКИЙ ГУАНОЗИН-3',5'-МОНОФОСФАТ-ФОСФОДИЭСТЕРАЗУ ТИПА 5 (cGMP PDE5), ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОГО РАССТРОЙСТВА |
| FR2762841B1 (fr) | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | Diazepino-indolones inhibitrices de phosphodiesterases iv |
| DE19881732D2 (de) | 1997-11-12 | 2000-08-24 | Bayer Ag | 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren |
| SK15532000A3 (sk) | 1998-04-20 | 2001-12-03 | Pfizer Inc. | Pyrazolopyrimidínové inhibítory cgmp pde5 na použitie na liečbu sexuálnych dysfunkcií, spôsob ich prípravy, medziprodukty a farmaceutický prostriedok s ich obsahom |
| DE19819023A1 (de) | 1998-04-29 | 1999-11-04 | Merck Patent Gmbh | Thienopyrimidine |
| TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
| KR100353014B1 (ko) | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
| ID30182A (id) | 1999-03-22 | 2001-11-08 | Bristol Myers Squibb Co | PENGHAMBAT-PENGHAMBAT PIRIDOPIRIDAZINA LEBURAN DARI cGMP FOSFODIESTERASE |
| AU767558B2 (en) | 1999-09-16 | 2003-11-13 | Mitsubishi Tanabe Pharma Corporation | Aromatic nitrogenous six-membered ring compounds |
| TW200400821A (en) | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| EE200300362A (et) | 2001-01-31 | 2003-12-15 | Pfizer Products Inc. | PDE4 isosüümide inhibiitoritena kasutatavad tiasolüül-, oksasolüül-, pürrolüül- ja imidasolüülhappeamiidi derivaadid |
| NZ526531A (en) * | 2001-01-31 | 2005-02-25 | Pfizer Prod Inc | Ether derivatives useful as inhibitors of phosphodiesterase type IV (PDE4) isozymes |
| US20020165962A1 (en) * | 2001-02-28 | 2002-11-07 | Alvarez Mario F. | Embedded controller architecture for a modular optical network, and methods and apparatus therefor |
| DE10135815A1 (de) | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| PL369738A1 (en) * | 2001-11-05 | 2005-05-02 | Merck Patent Gmbh | Hydrazono-malonitriles |
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| AU2003232148A1 (en) * | 2002-05-16 | 2003-12-02 | Pharmacia Corporation | A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases |
| WO2004072079A1 (en) | 2003-02-11 | 2004-08-26 | Pfizer Limited | Hydrated and anhydrous sildenafil hemi-citrate compound |
| US20060239927A1 (en) * | 2003-03-31 | 2006-10-26 | Kyowa Hakko Kogyo Co., | Drug for airway administration |
| EA012279B1 (ru) * | 2003-05-22 | 2009-08-28 | Никомед Гмбх | Композиция, включающая ингибитор pde4 и ингибитор pde5 |
| WO2004105751A1 (en) | 2003-05-28 | 2004-12-09 | Glaxo Group Limited | Traitement of cardiovascular pathology |
| US7132435B2 (en) | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
| US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317498D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
| US20050148555A1 (en) * | 2003-08-22 | 2005-07-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating COPD and pulmonary hypertension |
| AU2005234783A1 (en) | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension |
-
2006
- 2006-04-12 AU AU2006237300A patent/AU2006237300B2/en not_active Ceased
- 2006-04-12 EP EP11168764.6A patent/EP2366393B1/en active Active
- 2006-04-12 US US11/918,397 patent/US8648100B2/en not_active Expired - Fee Related
- 2006-04-12 DK DK11168764.6T patent/DK2366393T3/da active
- 2006-04-12 MX MX2007012711A patent/MX2007012711A/es active IP Right Grant
- 2006-04-12 EP EP06725734A patent/EP1874309A1/en not_active Withdrawn
- 2006-04-12 ES ES11168764T patent/ES2433661T3/es active Active
- 2006-04-12 ME MEP-2013-129A patent/ME01609B/me unknown
- 2006-04-12 BR BRPI0610498-3A patent/BRPI0610498A2/pt not_active IP Right Cessation
- 2006-04-12 JP JP2008507056A patent/JP2008536888A/ja active Pending
- 2006-04-12 PL PL11168764T patent/PL2366393T3/pl unknown
- 2006-04-12 RS RS20130378A patent/RS52944B/en unknown
- 2006-04-12 EA EA200702201A patent/EA016037B1/ru not_active IP Right Cessation
- 2006-04-12 SI SI200631678T patent/SI2366393T1/sl unknown
- 2006-04-12 CN CN2012100507411A patent/CN102614176A/zh active Pending
- 2006-04-12 KR KR1020077026282A patent/KR101358479B1/ko not_active IP Right Cessation
- 2006-04-12 CA CA2604295A patent/CA2604295C/en not_active Expired - Fee Related
- 2006-04-12 WO PCT/EP2006/061557 patent/WO2006111495A1/en active Application Filing
- 2006-04-12 CN CNA2006800130225A patent/CN101163476A/zh active Pending
- 2006-04-12 PT PT111687646T patent/PT2366393E/pt unknown
- 2006-04-12 NZ NZ561746A patent/NZ561746A/en not_active IP Right Cessation
-
2007
- 2007-09-17 ZA ZA200707930A patent/ZA200707930B/en unknown
- 2007-10-10 IL IL186538A patent/IL186538A0/en not_active IP Right Cessation
- 2007-11-07 NO NO20075662A patent/NO20075662L/no not_active Application Discontinuation
-
2012
- 2012-03-20 IL IL218745A patent/IL218745A0/en unknown
-
2013
- 2013-07-16 JP JP2013147501A patent/JP2013237683A/ja active Pending
- 2013-10-09 CY CY20131100878T patent/CY1114468T1/el unknown
- 2013-10-16 HR HRP20130982TT patent/HRP20130982T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1948176T3 (da) | Diarylurinstoffer til behandling af pulmonær hypertension | |
| CY2016017I1 (el) | Συνθεση για θεραπεια πνευμονικης υπερτασης | |
| DK1893586T3 (da) | Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler | |
| DK1828164T3 (da) | Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider | |
| DK1778668T3 (da) | Fremgangsmåde til fremstilling af dihydropteridion | |
| DK1877232T3 (da) | Fremgangsmåde til behandling af træoverflader | |
| DK1860941T3 (da) | Biphenyl-N-(4-pyridyl)methylsufonamider | |
| DK2084151T3 (da) | Substituerede dihydropyrazoloner til behandling af kardiovaskulære og hæmatologiske sygdomme | |
| DK1962830T3 (da) | Azaindolhæmmere af aurorakinaser. | |
| DK3403657T3 (da) | Anvendelse af oligouronater til behandling af slimhyperviskositet | |
| DE602005023972D1 (de) | Vereinfachte wafer-ausrichtung | |
| DE602006012066D1 (de) | Daraus | |
| DK1943406T3 (da) | Byggeelement | |
| DK1943243T3 (da) | Kinase-inhibitorer | |
| DK1773787T3 (da) | Fremgangsmåde til fremstilling af 3-phenyl(thio)uraciler og -dithiouraciler | |
| DE502006001027D1 (de) | Cyanuraten | |
| DK1907374T3 (da) | Til behandling af gastrointestinale sygdomme anvendelige benzylpiperazin-derivater | |
| DK1831223T3 (da) | Fremgangsmåde til fremstilling af L-biopterin | |
| ATE520664T1 (de) | Tyrosinkinase-hemmer | |
| DK1881830T3 (da) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet | |
| DK2366393T3 (da) | Roflumilast til behandlingen af pulmonal hypertension | |
| DK1814555T3 (da) | S-mirtazapin til behandling af hedeture | |
| DK1856035T3 (da) | Fremgangsmåde til fremstilling af beskyttelse amidiner | |
| DK1912961T3 (da) | Fremgangsmåde til fremstilling af bepromolin | |
| DK2044099T3 (da) | Fremgangsmåde til fremstillingen af s-fluormethyl-6,9-difluor-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1,4-dien-17-carbothiat og mellemprodukter |